
Dr. Pooja Babbar 
MBBS, MD, DM, Diploma, MBA
Medical Oncologist
Consultant
12 Years of Experience
English, Hindi
About Dr. Pooja Babbar
Dr. Pooja Babbar is a distinguished Consultant and Unit Head in Medical Oncology at Fortis Hospital, Manesar. She earned her MBBS with top honors from Maharashtra University of Health Sciences, followed by an MD in Radiation Oncology from Tata Memorial Hospital, Mumbai. She is a gold medalist in her DM (Medical Oncology) from Kidwai Memorial Institute of Oncology (RGUHS). With expertise in both solid and hematological cancers, she delivers personalized, evidence-based care, staying updated with global oncology protocols. Her compassionate approach ensures patients receive holistic and empathetic support across the cancer care continuum.
Qualifications of Dr. Pooja Babbar
- MBBS – Maharashtra University of Health Sciences
- MD – Radiation Oncology, Tata Memorial Hospital
- DM – Medical Oncology, Kidwai Memorial Institute (Gold Medalist)
- European Certification in Medical Oncology (ESMO)
- Diploma in Medico-Legal Education
- MBA in Hospital Management
Special Area of Interest
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Precision Oncology
- Cancer Screening and Early Detection
- Palliative Care
- Oncological Emergencies
- Multidisciplinary Tumour Board Discussions
- Solid Tumours (Head & Neck, Thoracic, Breast, Gastrointestinal, Genitourinary, Gynaecological)
- Haematological Malignancies (Lymphoma, Multiple Myeloma, Chronic Leukaemia)
- Neuro-oncology, Skin, Soft Tissue and Bone Tumours, Endocrine & Neuroendocrine Neoplasms
Work Experience of Dr. Pooja Babbar
- Consultant & Unit Head – Medical Oncology, Fortis Hospital, Manesar (current)
- Consultant Medical Oncologist – American Oncology Institute, Gurugram
- Consultant Medical Oncologist – CK Birla Hospital, Gurugram
- Senior Resident – Tata Memorial Hospital, Mumbai
Awards & Recognition
- Gold Medal for MBBS performance, MUHS
- Gold Medal in DM (Medical Oncology), Kidwai Memorial Institute, RGUHS
Membership
- European Society for Medical Oncology (ESMO)
- Likely active associations with national oncology societies and tumour boards in India
Research Paper Published By Dr. Pooja Babbar
- Cardiotoxic Effect of Chemotherapeutic Agents – European Journal of Molecular & Clinical Medicine, 2020
- Carboplatin with 3-Weekly Paclitaxel as First-Line Therapy in Recurrent/Metastatic Head & Neck Cancers – Oncology Journal of India, 2021
- Primary Neuroendocrine Tumor of the Testis: A Rare Case Report – Journal of MAR Oncology
- p16 Protein Expression as a Predictive Biomarker for Osteosarcoma Response to Neoadjuvant Chemotherapy – Annals of Oncology, 2020 (Abstract)
- Predictive Value of Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer – Annals of Oncology, 2020 (Abstract)
- Primary Tracheal Cancer: A Regional Cancer Center Experience – Oncology Journal of India, 2021
- Combined Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as a Biomarker in TNBC Patients – Submitted to Oncology Journal of India, 2021
- p16 Protein Expression in Osteosarcoma – Submitted to South Asian Journal of Cancer, 2021





Contact With Dr. Pooja Babbar
Frequently Asked Questions
Dr. Pooja Babbar treats a wide range of cancers including breast cancer, lung cancer, head and neck cancers, gynaecological cancers, gastrointestinal malignancies, genitourinary cancers, as well as hematological cancers such as lymphoma, multiple myeloma, and chronic leukaemia.
She has around 11 years of professional experience after completing her MBBS, with advanced training in radiation oncology and a gold medal in DM (Medical Oncology).
Yes, Dr. Babbar is highly skilled in modern oncology treatments such as immunotherapy, targeted therapy, hormonal therapy, and precision oncology, ensuring patients benefit from globally approved, evidence-based protocols.
Her approach combines medical excellence with compassionate patient support. She emphasizes holistic cancer care, including palliative management, oncological emergencies, and multidisciplinary tumour board discussions for individualized treatment planning.